Table 2.

Results of univariate analysis for survival

	From diagnosis				From progression
Variables	1‑year OS (%)	p-value	1‑year PFS (%)	p-value	1‑year OS (%)	p-value
Age (< vs. ≥ 8 years)	73 vs. 67	0.89	40 vs. 33	0.69	21 vs. 6	0.74
Gender (male vs. female)	69 vs. 70	0.22	54 vs. 25	0.33	25 vs. 5	0.16
Tumor volume (< vs. ≥ 59 cc)	81 vs. 51	0.03*	56 vs. 18	0.006*	20 vs. 7	0.02*
Contrast enhancement (yes vs. no)	71 vs. 67	0.52	56 vs. 29	0.21	15 vs. 13	0.87
Initial RT EQD2 (> vs. ≤ 54 Gy)	66 vs. 71	0.25	50 vs. 33	0.22	–	–
Concurrent CHT (yes vs. no)	75 vs. 61	0.33	45 vs. 23	0.03*	–	–
Time to progression (< vs. ≥ 8 months)	27 vs. 91	0.001*	–	–	18 vs. 11	0.74
Re-irradiation (yes vs. no)	87 vs. 56	0.04*	–	–	27 vs. 0	0.01*
Re-irradiation EQD2 (> vs. ≤ 24 Gy)	–	–	–	–	29 vs. 12.5	0.18

CHT chemotherapy, EQD2 equivalent dose in 2‑Gy fractions, OS overall survival, PFS progression-free survival, RT radiotherapy

*Statistically significant p-value